RHYTHM PHARMACEUTICALS, INC. financial data

Symbol
RYTM on Nasdaq
Location
Boston, MA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 04 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 347% % -27%
Quick Ratio 17% % 4.3%
Debt-to-equity 508% % 85%
Return On Equity -433% % -18%
Return On Assets -46% % 40%
Operating Margin -107% %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 66,736,056 shares 8.6%
Common Stock, Shares, Outstanding 66,684,077 shares 8.5%
Entity Public Float $2,400,000,000 USD 171%
Common Stock, Value, Issued $67,000 USD 9.8%
Weighted Average Number of Shares Outstanding, Basic 66,261,055 shares 8.2%
Weighted Average Number of Shares Outstanding, Diluted 66,261,055 shares 8.2%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $174,334,000 USD 54%
Research and Development Expense $166,475,000 USD -27%
Costs and Expenses $360,540,000 USD -4.6%
Operating Income (Loss) $186,206,000 USD 30%
Nonoperating Income (Expense) $5,717,000 USD -179%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $191,923,000 USD 26%
Income Tax Expense (Benefit) $439,000 USD
Net Income (Loss) Attributable to Parent $192,362,000 USD 26%
Earnings Per Share, Basic -3 USD/shares 29%
Earnings Per Share, Diluted -3 USD/shares 29%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $52,078,000 USD 9.6%
Cash, Cash Equivalents, and Short-term Investments $416,100,000 USD 39%
Accounts Receivable, after Allowance for Credit Loss, Current $33,034,000 USD 71%
Inventory, Net $22,107,000 USD 59%
Other Assets, Current $8,802,000 USD 32%
Assets, Current $494,802,000 USD 45%
Other Long-term Investments $2,473,000 USD -79%
Property, Plant and Equipment, Net $237,000 USD -70%
Operating Lease, Right-of-Use Asset $3,158,000 USD -12%
Other Assets, Noncurrent $7,326,000 USD -51%
Assets $506,874,000 USD 39%
Accounts Payable, Current $13,631,000 USD 179%
Accrued Liabilities, Current $59,314,000 USD 33%
Liabilities, Current $104,267,000 USD 6.8%
Operating Lease, Liability, Noncurrent $3,515,000 USD -13%
Other Liabilities, Noncurrent $35,596,000 USD
Liabilities $211,191,000 USD 0.15%
Accumulated Other Comprehensive Income (Loss), Net of Tax $926,000 USD -53%
Retained Earnings (Accumulated Deficit) $1,304,372,000 USD -17%
Stockholders' Equity Attributable to Parent $148,817,000 USD 1227%
Liabilities and Equity $506,874,000 USD 39%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $40,351,000 USD 0.96%
Net Cash Provided by (Used in) Financing Activities $32,499,000 USD 666%
Net Cash Provided by (Used in) Investing Activities $24,812,000 USD -17%
Common Stock, Shares Authorized 120,000,000 shares 0%
Common Stock, Shares, Issued 66,684,077 shares 8.5%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $16,958,000 USD
Deferred Tax Assets, Valuation Allowance $325,503,000 USD 22%
Deferred Tax Assets, Gross $326,704,000 USD 22%
Operating Lease, Liability $4,030,000 USD 180%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $198,070,000 USD 24%
Lessee, Operating Lease, Liability, to be Paid $5,909,000 USD 278%
Property, Plant and Equipment, Gross $5,399,000 USD -0.02%
Operating Lease, Liability, Current $624,000 USD
Lessee, Operating Lease, Liability, to be Paid, Year Two $1,103,000 USD 120%
Lessee, Operating Lease, Liability, to be Paid, Year One $456,000 USD -46%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $1,879,000 USD 1415%
Lessee, Operating Lease, Liability, to be Paid, Year Three $1,125,000 USD
Deferred Tax Assets, Operating Loss Carryforwards $167,375,000 USD 8.9%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four $1,148,000 USD
Additional Paid in Capital $1,454,048,000 USD 29%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance $1,201,000 USD 255%
Interest Expense $15,586,000 USD 55%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%